Sunday 24 June 2018

Eisai's breast cancer drug ‘extends lives’

Washington, June 7, 2010

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said.

The results of the Phase III trial, presented to a meeting of the American Society of Clinical Oncology in Chicago, should change practice, conference organizers told reporters. – Reuters

Tags: Breast cancer | Washington | Eisai | Eribulin |

More Health & Environment Stories

calendarCalendar of Events